- Home
- CANF vs JTAI Comparison
CANF vs JTAI Comparison
Compare CANF & JTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CANF | JTAI |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | Israel | United States |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.6M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | CANF | JTAI |
|---|---|---|
| Price | $3.32 | $0.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9,750.00 | $0.40 |
| AVG Volume (30 Days) | 609.7K | ★ 20.2M |
| Earning Date | 03-27-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $461.72 | N/A |
| Revenue Next Year | $290,391.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.08 |
| 52 Week High | $10.40 | $5.67 |
Technical Indicators
Market Signals| Indicator | CANF | JTAI |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 32.63 |
| Support Level | $0.60 | $0.09 |
| Resistance Level | $4.74 | $0.13 |
| Average True Range (ATR) | 0.64 | 0.01 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 0.54 | 30.53 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.